These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1124 related items for PubMed ID: 19188742

  • 1. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome.
    Blum WF, Cao D, Hesse V, Fricke-Otto S, Ross JL, Jones C, Quigley CA, Binder G.
    Horm Res; 2009; 71(3):167-72. PubMed ID: 19188742
    [Abstract] [Full Text] [Related]

  • 2. GH treatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial.
    Blum WF, Ross JL, Zimmermann AG, Quigley CA, Child CJ, Kalifa G, Deal C, Drop SL, Rappold G, Cutler GB.
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1383-92. PubMed ID: 23720786
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial.
    Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL, Braun L, Rappold G, SHOX Study Group.
    J Clin Endocrinol Metab; 2007 Jan; 92(1):219-28. PubMed ID: 17047016
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.
    Cutfield WS, Lundgren F.
    Horm Res; 2009 Jan; 71 Suppl 1():39-45. PubMed ID: 19153504
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect.
    Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, Gill A, Chaussain JL, Frisch H, Yturriaga R, Attanasio AF.
    J Pediatr; 2005 Jan; 146(1):45-53. PubMed ID: 15644821
    [Abstract] [Full Text] [Related]

  • 6. Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.
    Padidela R, Camacho-Hübner C, Attie KM, Savage MO.
    Horm Res; 2008 Jan; 70(3):129-36. PubMed ID: 18663312
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone treatment of girls with Turner syndrome: the National Cooperative Growth Study experience.
    Plotnick L, Attie KM, Blethen SL, Sy JP.
    Pediatrics; 1998 Aug; 102(2 Pt 3):479-81. PubMed ID: 9685447
    [Abstract] [Full Text] [Related]

  • 8. Effect of growth hormone therapy on severe short stature and skeletal deformities in a patient with combined Turner syndrome and Langer mesomelic dysplasia.
    Shah BC, Moran ES, Zinn AR, Pappas JG.
    J Clin Endocrinol Metab; 2009 Dec; 94(12):5028-33. PubMed ID: 19850687
    [Abstract] [Full Text] [Related]

  • 9. Growth hormone therapy in patients with short stature homeobox-gene (SHOX) deficiency.
    Iughetti L, Madeo S, Predieri B.
    J Endocrinol Invest; 2010 Jun; 33(6 Suppl):34-8. PubMed ID: 21057184
    [Abstract] [Full Text] [Related]

  • 10. [Effect of estrogen therapy on the growth of Turner syndrome in girls treated with growth hormone].
    Morin A, Guimarey L, Apezteguia M, Santucci Z.
    Medicina (B Aires); 2001 Jun; 61(3):271-4. PubMed ID: 11474872
    [Abstract] [Full Text] [Related]

  • 11. Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone.
    Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, Jacobs J, Lippe B.
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2338-44. PubMed ID: 19401366
    [Abstract] [Full Text] [Related]

  • 12. Impact of patient characteristics and clinical factors on the decision to initiate growth hormone treatment in Turner syndrome.
    Khatchadourian K, Huot C, Alos N, Van Vliet G, Deal C.
    Horm Res; 2008 Jul; 70(5):300-8. PubMed ID: 18824869
    [Abstract] [Full Text] [Related]

  • 13. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
    Binder G, Trebar B, Baur F, Schweizer R, Ranke MB.
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
    [Abstract] [Full Text] [Related]

  • 14. SHOX gene variants: growth hormone/insulin-like growth factor-1 status and response to growth hormone treatment.
    Shapiro S, Klein GW, Klein ML, Wallach EJ, Fen Y, Godbold JH, Rapaport R.
    Horm Res Paediatr; 2015 Apr; 83(1):26-35. PubMed ID: 25659810
    [Abstract] [Full Text] [Related]

  • 15. Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial.
    Benabbad I, Rosilio M, Child CJ, Carel JC, Ross JL, Deal CL, Drop SL, Zimmermann AG, Jia N, Quigley CA, Blum WF.
    Horm Res Paediatr; 2017 Apr; 87(1):42-50. PubMed ID: 28002818
    [Abstract] [Full Text] [Related]

  • 16. Treatment outcome in Turner syndrome.
    Parvin M, Roche E, Costigan C, Hoey HM.
    Ir Med J; 2004 Jan; 97(1):12, 14-5. PubMed ID: 15055914
    [Abstract] [Full Text] [Related]

  • 17. Radiological Features in Patients with Short Stature Homeobox-Containing (SHOX) Gene Deficiency and Turner Syndrome before and after 2 Years of GH Treatment.
    Child CJ, Kalifa G, Jones C, Ross JL, Rappold GA, Quigley CA, Zimmermann AG, Garding G, Cutler GB, Blum WF.
    Horm Res Paediatr; 2015 Jan; 84(1):14-25. PubMed ID: 25967354
    [Abstract] [Full Text] [Related]

  • 18. [Growth Hormone treatment in children with Growth Hormone deficiency, idiopathic short stature, SHOX gene mutation, small for gestational age and Turner syndrome].
    Griffero González M, González Navarrete D, Tolosa Navarro F, López Cuevas P, Rodríguez Convertino F, Román Reyes R.
    Andes Pediatr; 2024 Apr; 95(2):151-158. PubMed ID: 38801362
    [Abstract] [Full Text] [Related]

  • 19. The growth response to GH treatment is greater in patients with SHOX enhancer deletions compared to SHOX defects.
    Donze SH, Meijer CR, Kant SG, Zandwijken GR, van der Hout AH, van Spaendonk RM, van den Ouweland AM, Wit JM, Losekoot M, Oostdijk W.
    Eur J Endocrinol; 2015 Nov; 173(5):611-21. PubMed ID: 26264720
    [Abstract] [Full Text] [Related]

  • 20. Impaired GH secretion in patients with SHOX deficiency and efficacy of recombinant human GH therapy.
    Iughetti L, Vannelli S, Street ME, Pirazzoli P, Bertelloni S, Radetti G, Capone L, Stasiowska B, Mazzanti L, Gastaldi R, Maggio MC, Predieri B.
    Horm Res Paediatr; 2012 Nov; 78(5-6):279-87. PubMed ID: 23208451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.